ORGANIC
LETTERS
2003
Vol. 5, No. 2
117-120
Novel Orthogonal Strategy toward
Solid-Phase Synthesis of
1,3,5-Substituted Triazines
Jacqueline T. Bork, Jae Wook Lee, Sonya M Khersonsky, Ho-Sang Moon, and
Young-Tae Chang*
Department of Chemistry, New York UniVersity, New York, New York 10003
Received October 29, 2002
ABSTRACT
To improve upon the previous orthogonal method for synthesis of a triazine library, an alternative strategy has been developed via oxidation-
activation of the thioether to the sulfone. Through a comparison between these two methods, the sulfone strategy was demonstrated as an
enhanced method in the generation of highly pure triazine library compounds.
Triazine derivatives have demonstrated a broad range of
biological activities, including anti-angiogenesis,1 herbicidal
effects,2 anti-metastatic effects,3 Erm methyltransferase
inhibition,4and anti-microbial effects.5 With the advent of
combinatorial chemistry, several triazine libraries have been
published in the literature, both in solid6 and solution7 phase,
taking advantage of its easy manipulation and the low price
of starting material. However, all of the reported procedures
contain stepwise amination, which is difficult to generalize
for nucleophiles with varying reactivities, and thus each
reaction step may accumulate byproducts, yielding impure
library compounds.6,7
We have recently developed a unique orthogonal solid-
phase synthetic pathway for a highly pure trisubstituted
triazine library, in which certain members of the library
exhibited anti-tubulin activity.8 In this synthetic approach,
three types of building blocks were prepared separately and
assembled by chemically orthogonal reactions (Figure 1).
Although the strategy worked very nicely, giving highly pure
triazine library compounds, two problems were encountered.
(1) Ono, M.; Kawahara, N.; Goto, D.; Wakahayashi, Y.; Ushiro, S.;
Yoshida, S.; Izumi, H.; Kuwano, M.; Sato, Y. Cancer Res. 1996, 56, 1512-
1516.
(2) Draber, W.; Tietjen, K.; Kluth, J. F.; Trebst, A. Angew. Chem., Int.
Ed. Engl. 1991, 30, 1621-1633.
(3) Maeda, M.; Iogo, M.; Tsuda, H.; Fujita, H.; Yonemura, Y.; Nakagawa,
K.; Endo, Y.; Sasaki, T. Anti-Cancer Drug Des. 2000, 15, 217-223.
(4) Hajduk, P. J.; Dinges, J.; Schkeryantz, J. M.; Janowick, D.; Kaminski,
M.; Tufano, M.; Augeri, D. J.; Petros, A.; Nienaber, V.; Zhong, P.;
Hammond, R.; Coen, M.; Beutel, B.; Katz, L.; Fesik, S. W. J. Med. Chem.
1999. 42, 3852-3859.
(5) Silen, J. L.; Lu A. T.; Solas, D. W.; Gore, M. A.; MacLean, D.;
Shah, N. H.; Coffin, L. M.; Bhinderwala, N. S.; Wang, Y.; Tsutsui, K. T.;
Look, G. C.; Campbell, D. A.; Hale, R. L.; Navre, M.; Deluca-Flaherty, C.
R. Antimicrob. Agents Chemother. 1998, 42, 1447-1453.
(6) (a) Stankova, M.; Lebl, M. Mol. DiVersity 1996, 2, 75-80. (b) Scharn,
D.; Wenschuh, H.; Reineke, U.; Schneider-Mergener, J.; Germeroth, L. J.
Comb. Chem. 2000, 2, 361-369. (c) Teng, S. F.; Sproule, K.; Hussain, A.;
Lowe, C. R. J. Mol. Recognit. 1999, 12, 67-75. (d) Filippusson, H.;
Erlendsson, L. S.; Lowe, C. R. J. Mol. Recognit. 2000, 13, 370-381.
(7) (a) Gustafson, G. R.; Baldino, C. M.; O’Donnel, M. E.; Sheldon, A.;
Tarsa, R. J.; Verni, C. J.; Coffen, D. L. Tetrahedron 1998, 54, 4051-4065.
(b) Johnson, C. R.; Zhang, B.; Fantauzzi, P.; Hocker, M.; Yager, K. M.
Tetrahedron 1998, 54, 4097-4106. (c) Falorni, M.; Giacomelli, G.; Mameli,
L.; Pordheddu, A. Tetrahedron Lett. 1998, 39, 7607.
(8) Moon, H.; Jacobson, E.; Khersonsky, S. M.; Luzung, M.; Walsh,
D.; Xiong, W.; Lee, J. W.; Parikh, P.; Lam, J. C.; Kang, T. W.; Rosania,
G. F.; Schier, A.; Chang, Y. T. J. Am. Chem. Soc. 2002, 124, 11608-
11609.
10.1021/ol027195v CCC: $25.00 © 2003 American Chemical Society
Published on Web 01/01/2003